BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The Life Raft Group - ECPv6.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://liferaftgroup.org
X-WR-CALDESC:Events for The Life Raft Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211118T130000
DTEND;TZID=America/New_York:20211118T141500
DTSTAMP:20211101T192901Z
CREATED:20211013T191553Z
LAST-MODIFIED:20211101T192901Z
UID:10000174-1637240400-1637244900@liferaftgroup.org
SUMMARY:Immunotherapy and GIST
DESCRIPTION:As the landscape of GIST treatment continues to evolve\, the area of immunotherapy has grown interest. GIST contains tumor-infiltrating immune cells which opens the possibility to the rationale for immunotherapy treatments. This webinar will provide an overview of immunotherapy with some examples of studies exploring single agent versus combination of therapy in GIST. \n\nIf you have questions about this presentation\nor about registration\, please contact:\nSara Rothschild\, VP Program Services\, srothschild@liferaftgroup.org\nREGISTEROur Presenters\n\nJonathan Trent\, MD\nDirector\, Sarcoma Oncology\nSylvester Comprehensive Cancer Center\nMiami\, Florida \nDr. Trent is currently the Associate Director for Clinical Research\, the Director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center. Dr. Trent’s interests are in the clinical and translational research of sarcomas\, direct care of sarcoma patients\, and education about sarcoma. As Associate Director for Clinical Research\, his goal is to help Sylvester Faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to cancer patients of South Florida and beyond. The major focus of his clinical\, educational and research efforts are with gastrointestinal stromal tumor (GIST)\, chondrosarcoma\, and other sarcomas. The major efforts of Dr. Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials\, prospectively acquired tumor tissue\, cell lines\, archival tissue\, as well as collaborations with disciplines such as the genomics facility\, surgical oncology\, pathology\, radiology and interventional radiology. \nJunaid Arshad\, MD\nAssistant Professor & Clinical Scholar\nUniversity of Arizona Cancer Center\nTucson\, Arizona\n \nDr. Arshad finished his medical degree from King Edward Medical University\, Lahore Pakistan. He relocated to the United States in 2013 and worked as a research volunteer at Wayne State University\, Detroit. After completing his internal medicine residency training from St. Mary’s Hospital Waterbury\, CT\, he moved to University of Miami for his hematology and medical oncology fellowship. \nDr. Arshad developed interest in Gastrointestinal Stromal Tumors (GIST) after working with Dr. Jonathan Trent who was also his mentor at the University of Miami. Dr. Arshad has published several peer reviewed publications focusing on the use of ctDNA in GIST. Currently Dr. Arshad is working as an Assistant Professor at University of Arizona Cancer Center in the field of GI Medical Oncology focusing on the GIST and Upper GI cancers. \nArun Singh\, MD\nOncologist\, Sarcoma and Connective Tissue Medical Oncology\nUniversity of California Los Angeles Medical Center\nSan Monica\, California\n \nDr. Singh is an associate professor in the Department of Medicine\, Division of Hematology/Oncology at the David Geffen School of Medicine UCLA. Dr Singh is a hematologist and medical oncologist whose practice focuses on the treatment of bone and soft tissue sarcomas. Dr Singh’s research focus is on developing novel therapies for patients with sarcomas. In the preclinical setting\, he works on elucidating the mechanisms contributing to the promotion of growth in cancer cells and optimizing the use of targeted therapy in specific sarcoma subtypes. The insights gained from these efforts are then translated into the clinic in the form of new drugs in early stage phase 1 and 2 clinical trials for sarcomas where there is an unmet clinical need. \nRonald DeMatteo\, MD\, FACS\nSurgeon\, Endocrinology and Oncology\nPenn Medicine\nPhiladelphia\, Pennsylvania \nDr. DeMatteo is the Chairman of the Department of Surgery and a Surgical Oncologist who specializes in treating diseases of the liver\, bile duct\, gallbladder\, pancreas and abdominal sarcomas (GIST). His clinical research has focused on liver\, bile duct\, gallbladder\, and pancreas cancers. In addition\, he has led several national trials testing the benefit of imatinib mesylate (Gleevec) following surgery for gastrointestinal stromal tumor (GIST)\, a tumor that usually begins in the stomach or intestine. In the laboratory he and his colleagues study the immune environment of the liver and tumor immunology\, working to develop immune therapies to help prevent tumors from returning after surgery. \nThank you to our sponsors!
URL:https://liferaftgroup.org/event/immunotherapy-and-gist/
CATEGORIES:Events,Research
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201026T120000
DTEND;TZID=America/New_York:20201026T120000
DTSTAMP:20201022T161543Z
CREATED:20201002T183013Z
LAST-MODIFIED:20201022T161543Z
UID:10000089-1603713600-1603713600@liferaftgroup.org
SUMMARY:Women in Sarcoma: Case Presentations
DESCRIPTION:Case Presentations\nOctober 26\, 12PM ET \nPlease join us for the second webcast of our Women in Sarcoma series. The Life Raft Group has developed the Women in Sarcoma program in recognition of the many women sarcoma specialists that engage with the sarcoma patient community and focus on educating and advocating on behalf of those living with sarcoma. \nThis panel features three women sarcoma experts presenting unique case studies that they have encountered in their practices. Panelists will interact with each other about these case studies\, and participants will gain meaningful insight into how these experts diagnose and treat sarcoma patients\, and how they collaborate with colleagues toward the goal of achieving positive outcomes for these challenging cases. \n\nIf you have questions about this panel or about registration\, please contact Sara Rothschild\, VP Program Services \n\nPlease join us for this interactive session with women leading the field of sarcoma!\n\nREGISTEROur Panel of Experts\n \n\nVaia Florou\, MD\nOncologist\nUniversity of Utah\nHuntsman Cancer Center\n \n\nCiara Kelly\, MBBCh BAO\nOncologist\nMemorial Sloan Kettering\nCancer Center\n \n\n\nSandra R. Brackert\, NP\nNurse Practitioner\nRonald Reagan UCLA\nMedical Center
URL:https://liferaftgroup.org/event/women-in-sarcoma-case-presentations/
CATEGORIES:Education,Research,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2020/10/Women-In-Sarcoma-2.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190820T160000
DTEND;TZID=America/New_York:20190820T170000
DTSTAMP:20190906T143456Z
CREATED:20190812T150929Z
LAST-MODIFIED:20190906T143456Z
UID:10000038-1566316800-1566320400@liferaftgroup.org
SUMMARY:Informational Webinar on Avapritinib
DESCRIPTION:Informational Webinar on Avapritinib Clinical Trial Program in GIST – presented by Blueprint Medicines\n\nRECAP HERE\n\nTuesday\, August 20\, Blueprint Medicines is working with The Life Raft Group and GIST Support International to host a webinar providing a data update from the registration-enabling NAVIGATOR trial of the investigational treatment avapritinib in patients with PDGFRA Exon 18 mutant GIST and fourth-line GIST. These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1\, 2019. Please see here for the press release summarizing the data and the slides presented at ASCO. \nThe webinar will be held on August 20th beginning at 4:00 p.m.\, Eastern Time (1:00 p.m.\, Pacific Time).  Maria Roche\, Senior Medical Director at Blueprint Medicines\, will provide an overview of the data presented at ASCO and an update on ongoing or planned studies in multiple lines of GIST treatment. We invite patients with GIST and their families to participate in this informational webinar – see details to access the webinar below. \nPlease submit suggested questions that you would like to be addressed during the webinar to patients@blueprintmedicines.com by Thursday\, August 15th.
URL:https://liferaftgroup.org/event/informational-webinar-on-avapritinib/
CATEGORIES:Research,Webcast
ATTACH;FMTTYPE=image/png:https://liferaftgroup.org/wp-content/uploads/2019/08/blueprint-medicines-event.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190417T120000
DTEND;TZID=America/New_York:20190417T130000
DTSTAMP:20190730T152255Z
CREATED:20190404T133838Z
LAST-MODIFIED:20190730T152255Z
UID:10000022-1555502400-1555506000@liferaftgroup.org
SUMMARY:LRG Webcast: GI Stromal Tumors
DESCRIPTION:GI Stromal Tumors: A PatholoGIST’s Point of View – Mutational Testing in GIST\nLISTEN TO THE WEBCAST\n\nMutational Testing in GIST is a vital component for survival\, especially as cancer treatment becomes more individualized. In this webcast\, Dr. Chris Corless\, Director and Chief Medical Officer of the Knight Diagnostic Laboratories at OHSU\, demystifies the process by which pathologists make the diagnosis of GIST and assess the risk of recurrence. Dr. Corless will discuss how tumor DNA is extracted and analyzed from these tumors\, and how mutations detected in tumor DNA influences treatment decisions.\n\nThere will be a 15 minute Q & A at the end of his presentation.\n\nAbout the Presenter:\n\n\nAfter undergraduate studies at the Univ. of California\, Berkeley\, Dr. Corless received his MD and PhD degrees from Washington University\, St. Louis. He did his residency training in Anatomic Pathology at the Brigham & Women’s Hospital\, Boston\, where he also completed fellowship training in GI Pathology and GU Pathology. He joined the faculty of Oregon Health & Science University in 1994 and was promoted to Professor in 2004. During his career he has served as the residency program director in Pathology and medical director of surgical pathology for OHSU Hospital. He is presently the Director and Chief Medical Officer of the Knight Diagnostic Laboratories at OHSU. An author on over 260 publications\, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors. \n\n\nTechnical Tips to Join Meeting:\n\nThis is a web only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-gi-stromal-tumors-mutational-testing-in-gist/
CATEGORIES:Education,Events,Research,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/04/Corless-Webcast-alt.jpg
ORGANIZER;CN="The Life Raft Group":MAILTO:liferaft@liferaftgroup.org
END:VEVENT
END:VCALENDAR